Nuvectis Pharma, Inc. (NVCT)
| Market Cap | 438.47M +65.7% |
| Revenue (ttm) | n/a |
| Net Income | -29.59M |
| EPS | -1.30 |
| Shares Out | 26.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404,408 |
| Open | 13.84 |
| Previous Close | 13.82 |
| Day's Range | 13.02 - 16.64 |
| 52-Week Range | 5.55 - 16.57 |
| Beta | -0.07 |
| Analysts | Strong Buy |
| Price Target | 17.40 (+5.26%) |
| Earnings Date | Aug 4, 2026 |
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVCT stock is "Strong Buy." The 12-month stock price target is $17.4, which is an increase of 5.26% from the latest price.
News
Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital
Lucid Capital analyst Christopher Liu raised the firm’s price target on Nuvectis Pharma (NVCT) to $22 from $18 and keeps a Buy rating on the shares. The company announced a…
Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nuvectis Pharma (NVCT) to $39 from $13 and keeps a Buy rating on the shares. The firm says the company’s licensing agreement…
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group , targeting complement-mediated diseases and cancer to broaden...
Nuvectis Pharma Transcript: Status update
A transformative in-licensing deal brings two late-stage drug candidates, NXP100 and NXP200, into the pipeline, expanding focus to complement-mediated diseases and oncology. NXP100 offers once-daily oral dosing with strong efficacy, while NXP200 shows promise in multiple tumor types.
Nuvectis Pharma Press release: Status update
Nuvectis Pharma issued a press release on June 22, 2026, disclosing material business information to investors.
Nuvectis Pharma announces license agreement with Haisco for two compounds
Nuvectis Pharma (NVCT) announced a strategic portfolio expansion via a license agreement for exclusive ex-China rights with Haisco Pharmaceutical to two clinical-stage compounds. NXP100 is a once-dail...
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative ...
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nuvectis Pharma (NVCT) to $13 from $10 and keeps a Buy rating on the shares. The firm increased its probability of success…
Nuvectis Pharma Transcript: AGM 2026
The meeting confirmed a quorum and approved both the election of a director for a term through 2029 and the ratification of the independent auditor for 2026. Full voting results will be filed with the SEC and made available online.
Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
NXP900, a highly selective SRC inhibitor, shows strong safety and potency in early trials, achieving up to 95% SRC inhibition and avoiding major side effects. Ongoing Phase I-B trials target enriched patient populations and include combinations with leading lung cancer therapies, addressing a large market with substantial unmet need.
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p...
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma Earnings release: Q1 2026
Nuvectis Pharma released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Nuvectis Pharma Quarterly report: Q1 2026
Nuvectis Pharma has published its Q1 2026 quarterly earnings report on May 5, 2026.
Nuvectis Pharma Proxy statement: Proxy filing
Nuvectis Pharma filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Nuvectis Pharma Proxy statement: Proxy filing
Nuvectis Pharma filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma management to meet with Maxim
Meeting to be held on March 25 hosted by Maxim.
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Nuvectis Pharma files $150M mixed securities shelf
16:03 EST Nuvectis Pharma (NVCT) files $150M mixed securities shelf
Nuvectis Pharma Registration statement: Registration Filing
Nuvectis Pharma filed a registration statement on February 13, 2026, providing details about a securities offering with the SEC.
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
Nuvectis Pharma Earnings release: Q4 2025
Nuvectis Pharma released its Q4 2025 earnings on February 11, 2026, summarizing the period's financial results.
Nuvectis Pharma Annual report: Q4 2025
Nuvectis Pharma has published its Q4 2025 annual report on February 11, 2026.